HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Bio Recalls Due To Potential Microbial Contamination Approach 500

Executive Summary

FDA deemed 469 homeopathic remedies manufactured by King Bio – marketed as Dr. King’s: Natural Medicine, Aquaflora, SafeCareRx and Safecare bands – and recalled since July as class I, indicating the agency considers that a violative product poses reasonable probability of serious adverse health consequences or death. Kingston Pharma recalls one lot of DG/health Naturals baby Cough Syrup + Mucus potentially contaminated and Ata Int.'s BlueFusion product marketed as a dietary supplement contains ED ingredients and other drugs.

You may also be interested in...



FDA Warns On Releasing 'At Risk' Drugs, Making Supplements In Kitchen, Claims For Diatomaceous Earth

Kingston Pharma needs to review; McDaniel Life-Line risks contamination; Earthworks multi-channel marketing; ActiveHerb TCM Lines noncompliant; AMMD skips finished product tests; and PRL warned on GMPs, claims.

OTC Private Labeler RIJ Pharmaceutical Must 'Fully Remediate' Water System

FDA asks RIJ Pharmaceutical, which recalled a dozen products last year, to provide plans for developing a solid water system design and mixing process. It warns private label manufacturer about contaminated, "‘super-potency" OTC drugs that resulted from GMP violations.

King Bio Tops List Of Homeopathic Firms FDA Warns In Show Of Enforcement

FDA warns King Bio, three other homeopathic product marketers. In addition to GMP deficiencies, "we continue to see products labeled as homeopathic that are being marketed without approval for a wide array of diseases and conditions, from chronic pain to cancer,” says FDA Commissioner Gottlieb.

Related Content

Topics

UsernamePublicRestriction

Register

RS148649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel